{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:14:40Z","timestamp":1772126080514,"version":"3.50.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/md.0000000000003719","type":"journal-article","created":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T13:51:31Z","timestamp":1464875491000},"page":"e3719","source":"Crossref","is-referenced-by-count":39,"title":["Racial Disparities in Treatment Rates for Chronic Hepatitis C"],"prefix":"10.1097","volume":"95","author":[{"given":"Philip","family":"Vutien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nghia H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-12-20210309","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"R3-12-20210309","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1440-1746.2004.03381.x","article-title":"Ethnic and cultural determinants influence risk assessment for hepatitis C acquisition","volume":"19","author":"Dev","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"R4-12-20210309","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1111\/j.1365-2893.2011.01513.x","article-title":"Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients","volume":"19","author":"Ho","year":"2012","journal-title":"J Viral Hepat"},{"key":"R5-12-20210309","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1007\/s10620-013-2884-6","article-title":"Less-established risk factors are common in Asian Americans with hepatitis C virus: a case-controlled study","volume":"58","author":"Kin","year":"2013","journal-title":"Dig Dis Sci"},{"key":"R6-12-20210309","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/MCG.0b013e3182688b3e","article-title":"High proportion of hepatitis C virus in community Asian American patients with non-liver-related complaints","volume":"47","author":"Kin","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"R7-12-20210309","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/apt.12300","article-title":"Systematic review: Asian patients with chronic hepatitis C infection","volume":"37","author":"Nguyen","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-12-20210309","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"key":"R9-12-20210309","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/ajg.2014.214","article-title":"Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans","volume":"109","author":"El-Serag","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R10-12-20210309","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/ajg.2015.31","article-title":"Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study","volume":"110","author":"Ditah","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R11-12-20210309","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"R12-12-20210309","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa032502","article-title":"Atlantic Coast Hepatitis Treatment G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites","volume":"350","author":"Muir","year":"2004","journal-title":"N Engl J Med"},{"key":"R13-12-20210309","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2893.2009.01226.x","article-title":"Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2\/3 vs 6","volume":"17","author":"Nguyen","year":"2010","journal-title":"J Viral Hepat"},{"key":"R14-12-20210309","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1310\/hct1303-142","article-title":"Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial","volume":"13","author":"Rodriguez-Torres","year":"2012","journal-title":"HIV Clin Trials"},{"key":"R15-12-20210309","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/ajg.2009.635","article-title":"Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C","volume":"105","author":"Vutien","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R16-12-20210309","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ajg.2015.218","article-title":"Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and\/or ribavirin","volume":"110","author":"Shiffman","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R17-12-20210309","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27053","article-title":"All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naive patients with genotype 1 HCV infection","volume":"60","author":"Wyles","year":"2014","journal-title":"Hepatology"},{"key":"R18-12-20210309","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2013.10.057","article-title":"Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection","volume":"146","author":"Everson","year":"2014","journal-title":"Gastroenterology"},{"key":"R19-12-20210309","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.27826","article-title":"Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis","volume":"62","author":"Reddy","year":"2015","journal-title":"Hepatology"},{"key":"R20-12-20210309","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(14)71002-3","article-title":"Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial","volume":"15","author":"Reddy","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R21-12-20210309","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1572-0241.2005.00240.x","article-title":"Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes","volume":"100","author":"Cheung","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R22-12-20210309","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2105\/AJPH.2007.113225","article-title":"Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study","volume":"98","author":"Rousseau","year":"2008","journal-title":"Am J Public Health"},{"key":"R24-12-20210309","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"R25-12-20210309","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R26-12-20210309","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2011.05.032","article-title":"Gaps in the achievement of effectiveness of HCV treatment in national VA practice","volume":"56","author":"Kramer","year":"2012","journal-title":"J Hepatol"},{"key":"R27-12-20210309","first-page":"250","article-title":"Population-based hepatitis C surveillance and treatment in a national managed care organization","volume":"10","author":"Shatin","year":"2004","journal-title":"Am J Manag Care"},{"key":"R28-12-20210309","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10620-015-3621-0","article-title":"Poor sustained virological response in a multicenter real-life cohort of chronic hepatitis C patients treated with pegylated interferon and ribavirin plus telaprevir or boceprevir","volume":"60","author":"Vo","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R29-12-20210309","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/gut.2006.099150","article-title":"Rate and predictors of treatment prescription for hepatitis C","volume":"56","author":"Butt","year":"2007","journal-title":"Gut"},{"key":"R30-12-20210309","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/hep.24358","article-title":"Racial differences in hepatitis C treatment eligibility","volume":"54","author":"Melia","year":"2011","journal-title":"Hepatology"},{"key":"R31-12-20210309","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2105\/AJPH.2012.300858","article-title":"Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010","volume":"103","author":"Tohme","year":"2013","journal-title":"Am J Public Health"},{"key":"R32-12-20210309","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3122\/jabfm.2014.02.130246","article-title":"Racial and socioeconomic disparities in access to primary care among people with chronic conditions","volume":"27","author":"Shi","year":"2014","journal-title":"J Am Board Fam Med"},{"key":"R33-12-20210309","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000003719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:25:08Z","timestamp":1620959108000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201605310-00012"}},"subtitle":["Analysis of a Population-Based Cohort of 73,665 Patients in the United States"],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":31,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000003719","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}